GlaxoSmithKline (LON:GSK) received a GBX 1,600 ($22.91) target price from investment analysts at Jefferies Group in a research note issued to investors on Friday, April 13th. The brokerage currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 11.83% from the company’s previous close.
Several other research analysts have also recently issued reports on the company. Kepler Capital Markets reaffirmed a “hold” rating on shares of GlaxoSmithKline in a report on Thursday, April 12th. UBS set a GBX 1,600 ($22.91) price target on GlaxoSmithKline and gave the company a “buy” rating in a report on Thursday, April 5th. Credit Suisse Group upped their price target on GlaxoSmithKline from GBX 1,300 ($18.61) to GBX 1,450 ($20.76) and gave the company a “neutral” rating in a report on Tuesday, April 3rd. Morgan Stanley set a GBX 1,400 ($20.05) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Tuesday, April 3rd. Finally, Berenberg Bank boosted their target price on shares of GlaxoSmithKline from GBX 1,705 ($24.41) to GBX 1,780 ($25.49) and gave the company a “buy” rating in a research note on Wednesday, March 28th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of GBX 1,554.32 ($22.26).
GSK opened at GBX 1,430.80 ($20.49) on Friday. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($17.69) and a 1-year high of GBX 1,724.50 ($24.69).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.